eicosanoid


Also found in: Dictionary, Encyclopedia, Wikipedia.

eicosanoid

(ī′kō-sə-noid′)
n.
Any of a group of substances that are derived from arachidonic acid, including leukotrienes, prostaglandins, and thromboxanes.

eicosanoid

A 20-carbon cyclic fatty acid derived from arachidonic acid that is synthesised from membrane phospholipids. Eicosanoids and other arachidonic acid metabolites (e.g., HETE, HPETE, leukotrienes, prostaglandins and thromboxanes) are site-specific, increase during shock and after injury, and have diverse functions, including bronchoconstriction, bronchodilation, vasodilation and vasoconstriction.

eicosanoid

Physiology A 20-carbon cyclic fatty acid which with its arachidonic acid metabolites–eg, HETE, HPETE, leukotrienes, PGs, and thromboxanes, are site-specific, ↑ during shock and after injury, have diverse functions–eg, bronchoconstriction, bronchodilation, vasodilation, vasoconstriction. See Arachidonic acid, Bad eicosanoid, Good eicosanoid, Zone-favorable diet.

eicosanoid

(ī-kō′să-noyd″)
Any of several autocrine or paracrine cytokines formed from the metabolism of arachidonic acid. They include prostaglandins, thromboxanes, and leukotrienes.
References in periodicals archive ?
2], is metabolized by cyclooxygenases (COXs) and lipoxygenases (LOXs) to lipid mediators including prostaglandins (PGs) and leukotrienes (LTs), which are often referred to as eicosanoids (Fig.
Fixed oil of Nigella sativa and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation.
Hence, there is a growing interest in pharmacological modulation of eicosanoid production in attempt to control the evolution of T.
Competitive inhibition-EPA and DGLA compete for COX and LOX, thereby reducing the output of AA eicosanoids.
5, 2, 5, and 16 h, aliquots were taken out of the samples to allow for each 10-12 replicates of MxP Broad Profiling, MxP Catecholamines, and MxP Eicosanoids as described below.
Another significant difference between both groups of subjects was found in the initial values of ALA, possibly due to a higher eicosanoid biosynthesis from n-6 FA.
A second level of regulation, which determines the specific eicosanoid produced following PGH2 production, is via the expression of intermediate and terminal enzymes, which include cPGES and mPGES, prostacyclin synthase, and brain or hematopoietic isoforms of prostaglandin D synthase (bPGDS, hPGDS).
Ongoing investigations of eicosanoid metabolites in the laboratory have led to the discovery of novel therapeutic targets for cardiovascular diseases.
In fact, increased production of free radicals during muscle activity is results of oxidative phosphorylation in mitochondrial, synthesis of eicosanoid and by some enzymatic reactions (primarily xanthin oxidase) and these processes lead to oxidative modification of proteins, including the antioxidant enzymes, and at the same time reducing their protective care which results in pro-antioxidants imbalance.
Prostacyclin opposes the effects of thromboxane, a thrombogenic and atherogenic eicosanoid.
Lipoxins contain a trihydroxytetraene group and are members of the eicosanoid family that are produced within the vascular lumen, primarily via platelet- leukocyte transcellular biosynthesis.